BARDA Funding Opportunities

Helping biomedical innovators secure federal funding from proposal support to post-award management.

What Does BARDA Fund?

The Biomedical Advanced Research and Development Authority (BARDA) provides non-dilutive funding to accelerate innovation in medical countermeasures – including vaccines, therapeutics, and diagnostics – that protect public health and strengthen national preparedness.

Through Broad Agency Announcements (BAAs), Requests for Proposals (RFPs), and Other Transaction Agreements (OTAs), BARDA funds groundbreaking work in biodefense, pandemic response and advanced manufacturing.

BARDA Programs We Support

EverGlade works across BARDA’s full portfolio of programs, including but not limited to:

Rapid Response Partnership Vehicle (RRPV)

Facilitates public-private partnerships to rapidly develop medical countermeasures in preparation for and during health emergencies.

Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-C)

Advances biomanufacturing innovations to enhance production efficiency and scalability.

BARDA Alliance Network

Strengthens collaborations to expedite the delivery of vaccines, therapeutics, and diagnostics.

BARDA TechWatch

Enables innovators to present novel technologies or capabilities directly to BARDA for feedback and alignment.

Download Your Guide to BARDA Funding

Recent BARDA Funding Programs

BARDA BioMaP Seeks Agile, Distributed Drug Manufacturing for Medical Countermeasures

BARDA’s Growing Use of Hubs and Prize Competitions, Beyond SAM.gov

Four Takeaways from the 2026 RRPV General Membership Meeting

BARDA Previews TACTIC Program for Threat-Agnostic CBRN Therapeutics

BARDA’s Draft New Vaccine Platforms RPP Signals a Major Push for Adaptable Medical Countermeasures

BARDA Releases RFP for Pandemic Influenza Vaccine Medical Countermeasures

BARDA’s BioMaP-Consortium Seeks Vendor Managed Inventory Capabilities to Secure the Nation’s API Reserve

BARDA’s Next Big Investment Play: Pandemic Preparedness And Domestic Manufacturing

BARDA’s BioMaP Releases RPP on Domestic Manufacturing for Nitrile Gloves

Sustaining Nitrile Glove Capacity With BARDA’s PPE Manufacturing Push

BARDA Signals Major NPIVS Contract For Pandemic Influenza Vaccines And Adjuvants

BARDA Seeks Advanced Dermal Regeneration Solutions for Severe Burns

How EverGlade Supports Innovators

Why EverGlade?

Federal funding is our science. We create, support, and manage strategic partnerships between innovators and funding agencies to maximize the impact of investment dollars while accelerating our clients’ growth.

Proven in Highly Regulated Federal Environments

With over 50 programs actively managed, we bring hands-on experience across federal agencies in a number of industries, navigating the strategic, technical, and regulatory demands that define successful programs.

Technical & Regulatory Fluency That Drives Post-Award Success

We are PhD-level scientists, former U.S. Government COTRs and SETAs, and federal procurement, financial, cost accounting & compliance regulatory experts who bring diverse perspectives to every stage of the funding lifecycle.

Successful Transition from Program Design to Execution

We operate as an extension of your team — like a “think tank” — where the diverse skill sets of our experts help ensure your program is built to perform from day one.

Powered by Proprietary Program Infrastructure

Your team gains access to proprietary intellectual property developed across years of complex R&D and financial program execution, including standardized tools, templates, and processes.

Ready to Pursue BARDA Funding?

Have a question or ready to discuss your project? Our team can help determine eligibility, align your proposal with agency priorities, and guide you through every step of the process.

BARDA Funding FAQ

What is BARDA?

BARDA (Biomedical Advanced Research and Development Authority), part of HHS's Administration for Strategic Preparedness and Response, funds the advanced development and manufacturing of medical countermeasures, including vaccines, therapeutics, diagnostics, and antibiotics for pandemic and biothreat response. Funding flows through BAAs, rapid solicitations via partners like RRPV, and Project BioShield procurements. EverGlade helps companies align a product candidate to the right BARDA solicitation.

What does BARDA fund?

BARDA funds the advanced development of vaccines, therapeutics, diagnostics, medical devices, and other technologies that strengthen national preparedness against public health emergencies. One 2026 Project BioShield award, for example, was funded at $119 million with options up to $482 million. EverGlade guides clients through BARDA's technical, regulatory, and commercialization requirements.

How does BARDA's funding process work?

BARDA funding typically starts with an initial white paper or abstract responding to a BAA, RRPV, or other targeted solicitation, followed by a full proposal covering technical approach, regulatory strategy, and budget if invited. Proposals are evaluated on scientific merit, feasibility, and public health impact before moving to negotiation and award. EverGlade supports clients at every stage of this process, from opportunity identification through post-award execution.

Does BARDA fund startups?

Yes, BARDA regularly supports startups and emerging companies developing innovative medical countermeasure technologies alongside established industry partners. Eligibility requirements vary by specific funding opportunity. EverGlade helps early-stage and growth companies position their technology competitively for BARDA funding.